MannKind Corporation (MNKD)
| Market Cap | 1.27B -8.4% |
| Revenue (ttm) | 393.63M +30.5% |
| Net Income | -43.61M |
| EPS | -0.16 |
| Shares Out | 321.54M |
| PE Ratio | n/a |
| Forward PE | 52.63 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,990,111 |
| Open | 4.060 |
| Previous Close | 4.060 |
| Day's Range | 3.930 - 4.075 |
| 52-Week Range | 2.230 - 6.510 |
| Beta | 1.10 |
| Analysts | Strong Buy |
| Price Target | 7.97 (+101.77%) |
| Earnings Date | Aug 5, 2026 |
About MNKD
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in... [Read more]
Financial Performance
In 2025, MannKind's revenue was $348.97 million, an increase of 22.23% compared to the previous year's $285.50 million. Earnings were $5.86 million, a decrease of -78.75%.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for MNKD stock is "Strong Buy." The 12-month stock price target is $7.97, which is an increase of 101.77% from the latest price.
News
MannKind price target lowered to $13 from $14 at Wells Fargo
Wells Fargo lowered the firm’s price target on MannKind (MNKD) to $13 from $14 and keeps an Overweight rating on the shares. The firm believes that good execution on product…
MannKind reports Q2 EPS (6c), consensus 2c
Reports Q2 revenue $109.37M, consensus $108.8M. “This was a transformative period for MannKind (MNKD), during which we delivered all three major catalysts we set out to achieve in 2026,” said…
MannKind Earnings Call Transcript: Q2 2026
Q2 revenue grew 43% year-over-year, driven by strong Afrezza and FUROSCIX sales, with pediatric Afrezza launch and FUROSCIX ReadyFlow approval marking key milestones. Guidance for FUROSCIX remains $110M–$120M, with margin expansion expected as ReadyFlow ramps.
MannKind Earnings release: Q2 2026
MannKind released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
MannKind Quarterly report: Q2 2026
MannKind has published its Q2 2026 quarterly earnings report on August 5, 2026.
MannKind Slides: Q2 2026
MannKind has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update
Achieved three major catalysts to drive future growth: Launched the pediatric indication of Afrezza ® following FDA approval FUROSCIX ReadyFlow™ autoinjector approved for treatment of edema in HF and ...
MannKind price target raised to $14 from $11 at Wells Fargo
Wells Fargo raised the firm’s price target on MannKind (MNKD) to $14 from $11 on higher Furoscix and ‘201 probability of success, while keeping an Overweight rating on the shares.
MannKind Transcript: Study result
Phase I-B results for nintedanib DPI in IPF patients showed strong safety and tolerability, with no serious adverse events or GI issues and only mild, transient cough in a minority of patients. The Technosphere platform enables efficient lung delivery, and phase II is underway to further assess safety and efficacy in a broader patient population.
MannKind Press release: Study result
MannKind issued a press release on July 29, 2026, disclosing material business information to investors.
MannKind Slides: Study result
MannKind has posted slides in relation to its latest quarterly earnings report, which was published on July 29, 2026.
MannKind injection helps heart failure patients avoid ER infusions
We also report on an experimental diagnostic approach that can detect tuberculosis exposure and infection at an earlier stage than current methods.
MannKind reports ‘positive’ Phase 1b INFLO-1 results
MannKind (MNKD) announced positive topline results from INFLO-1, its Phase 1b randomized, double-blind, placebo-controlled study evaluating nintedanib dry powder inhalation in patients with idiopathic...
MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF
MNKD Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety & Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF
MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), today announced that the Company will report second quarter 2026 financial results a...
MannKind Transcript: FDA announcement
FDA approved FUROSCIX ReadyFlow, a rapid auto-injector for IV-equivalent furosemide, enabling at-home treatment for fluid overload. Clinical studies confirmed bioequivalence and safety, with launch activities and real-world evidence generation underway. Major cost savings and broad adoption are anticipated.
MannKind Press release: FDA announcement
MannKind issued a press release on July 24, 2026, disclosing material business information to investors.
MannKind Slides: FDA announcement
MannKind has posted slides in relation to its latest quarterly earnings report, which was published on July 24, 2026.
MannKind announces FDA approval of Furoscix ReadyFlow
MannKind (MNKD) announced that the U.S. FDA has approved Furoscix ReadyFlow for the treatment of edema in adults with heart failure or chronic kidney disease. Furoscix ReadyFlow is an at-home…
MannKind announces $50M private placement
MannKind (MNKD) announced that it has entered into a securities purchase agreement in connection with a private placement to certain institutional investors. The gross proceeds from the private placem...
MannKind Announces $50 Million Private Placement
DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease
MannKind announces FDA approval of Furoscix ReadyFlow™, the first & only autoinjector delivering IV-equivalent diuretic therapy for the treatment of edema
MannKind nearing ‘underappreciated catalyst,’ says H.C. Wainwright
H.C. Wainwright views the July 26 FDA action date for the Furoscix ReadyFlow Autoinjector as an “underappreciated catalyst” for MannKind (MNKD) shares. Approval could materially improve the growth and...
MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D
Collaboration underscores interest in inhaled insulin and strengthens bringing innovation and new options to pediatric diabetes care DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind's Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems
Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and AID Use